Skip to main content
SpringerLink
Log in

Continued need to reduce lymphatic filariasis burden

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Mathew CG, et al. The health and economic burden of lymphatic filariasis prior to mass drug administration programmes. Clinical Infectious Diseases : 25 Jul 2019. Available from: URL: http://doi.org/10.1093/cid/ciz671

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Continued need to reduce lymphatic filariasis burden. PharmacoEcon Outcomes News 834, 10 (2019). https://doi.org/10.1007/s40274-019-6110-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-019-6110-4

Search

Navigation